Characteristics of cohorts I (use of sodium-glucose cotransporter 2 inhibitors [SGLT2i]) and II (no use of SGLT2i) before and after propensity score matching for age, gender distribution, and prevalence of diabetes mellitus, human immunodeficiency virus infection, alcohol abuse, liver diseases, and use of immune suppressants. The gene discussed is SLC5A2; the disease is liver disorder.